Fate Therapeutics Inc (NAS:FATE)
$ 3.68 0.23 (6.67%) Market Cap: 418.90 Mil Enterprise Value: 111.25 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 58/100

Fate Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 03:45PM GMT
Release Date Price: $34.05 (+8.75%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Okay. (inaudible) time we start it. So first and foremost, Glad I could make it down to Miami. Really please to see everybody. Hope it's a productive series of days for you and excited after 2-year hiatus of doing these. We're back to -- getting back to normal. So that's great. My name is Peter Lawson. I'm the moderator of this talk with Fate Therapeutics. Really welcome to Edward Dulac, CFO of Fate's.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

And I guess the first question I've really got is, I've asked this to many of our companies, but just like how you're differentiated within that cell therapy space?

Edward J. Dulac
Fate Therapeutics, Inc. - CFO & Principal Accounting Officer

Yes. Thanks, Peter, and thanks for having us. It's good to be back in person. So yes, I mean, we're cell-based cancer immunotherapy company, and we are working on and pioneering a new

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot